WSJ -- The head of Abbott Laboratories’ (ABT) U.S. pharmaceutical business will retire, and the medical-products company is combining its American and international patented-drug businesses into one organization.
WSJ -- The head of Abbott Laboratories’ (ABT) U.S. pharmaceutical business will retire, and the medical-products company is combining its American and international patented-drug businesses into one organization.
